Der Kaninchen Polyklonal Anti-SPHK2-Antikörper wurde für WB und IHC (p) validiert. Er ist geeignet, SPHK2 in Proben von Human zu detektieren. Es sind 2+ Publikationen verfügbar.
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Klon
RB03625
Bindungsspezifität
AA 590-620, C-Term
Aufreinigung
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This SPHK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 590-620 amino acids from the C-terminal region of human SPHK2.
Coste, Brenneis, Linke, Pierre, Maeurer, Becker, Schmidt, Gao, Geisslinger, Scholich: "Sphingosine 1-phosphate modulates spinal nociceptive processing." in: The Journal of biological chemistry, Vol. 283, Issue 47, pp. 32442-51, (2008) (PubMed).
Target
SPHK2
(Sphingosine Kinase 2 (SPHK2))
Andere Bezeichnung
SPHK2
Hintergrund
Sphingosine Kinase (SphK) catalyzes the phosphorylation of the lipid sphingosine, creating the bioactive lipid sphingosine-1-phosphate (S1P). S1P subsequently signals through cell surface G protein-coupled receptors, as well as intracellularly, to modulate cell proliferation, survival, motility and differentiation. SphK is an important signaling enzyme which is activated by diverse agents, including growth factors that signal through receptor tyrosine kinases, agents activating G protein-coupled receptors, and immunoglobulin receptors. Two SphK isotypes, SphK-1 and SphK-2, have been cloned, and both isotypes are ubiquitously expressed. SphK-1 has been shown to mediate cell growth, prevention of apoptosis, and cellular transformation, and is upregulated in a variety of human tumors. In contrast, SphK-2 increases apoptosis, and may be responsible for phosphorylating and activating the immunosuppressive drug FTY720.